Skip to main content

Lucid Diagnostics Inc.

corporate_fare Company Profile

Lucid Diagnostics Inc.

LUCD·NASDAQ·Industrial Applications And Services·CIK 0001799011

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on cancer prevention. The company targets millions of patients with gastroesophageal reflux disease (GERD), or chronic heartburn, who are at risk of developing esophageal precancer and esophageal adenocarcinoma (EAC). Lucid's primary product is the EsoGuard Esophageal DNA Test, which uses samples collected with the EsoCheck Esophageal Cell Collection Device. Lucid believes this combination is the first and only commercially available diagnostic test designed to prevent EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The EsoGuard test is a bisulfite-converted targeted next-generation sequencing (NGS) DNA assay. It quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1), using surface esophageal cells. Analytical validation tests showed EsoGuard has approximately 97% analytical sensitivity, 95% analytical specificity, 98% analytical accuracy, and 100% inter-assay and intra-assay precision. In screening studies, EsoGuard demonstrated a positive predictive value (PPV) of 30-33% and a negative predictive value (NPV) of 99% for detecting Barrett's esophagus (BE) and EAC. The EsoCheck device, which is FDA 510(k)-cleared and CE Mark certified, is a noninvasive swallowable balloon capsule catheter. It is designed for in-office targeted sampling of surface esophageal cells in a procedure lasting less than two minutes. The device consists of a vitamin-sized semi-rigid plastic capsule tethered to a thin silicone catheter, from which a soft inflatable silicone balloon with textured ridges emerges to swab cells.

Lucid Diagnostics Inc. (NASDAQ:LUCD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for LUCD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for LUCD spans 10-Q, 8-K, DEF 14A, PRE 14A.

Recent high-impact activity:

  • Lucid 10-Q: Going Concern Reaffirmed as Cash Falls to $18.0M and Note Conversion Price Resets to $0.3519
  • Lucid Posts $1.2M Q3 Revenue as Medicare Starts Paying for EsoGuard
  • Medicare Now Paying for EsoGuard; Q3 Revenue $1.2M, Record October Volume
  • Lucid Diagnostics Starts Collecting Medicare Payment for EsoGuard, Closes $15M Preferred Financing
  • Lucid Diagnostics Raises $15M in Series C Preferred Priced at $0.3519 Conversion

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.71M
Net Income
-$58.01M
Op. Cash Flow
-$46.48M
Free Cash Flow
-$46.68M
Gross Profit
-$1.96M
Operating Income
-$49.64M
Cash & Equivalents
$34.7M
Debt / Equity
0.00×
Net Margin
-12.33×
Shares Outstanding
131.1M sh
Source: 10-K · filed 2026-03-25 · accession 0001437749-26-009805

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 14,987,206 shares in LUCD as of the October 30, 2026 settlement, a 10.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 64.0% of LUCD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)14,987,206 shares as of October 30, 2026
Change vs prior period▲ 10.0%
Days to cover1.00 at avg daily volume of 21,872,292
Daily short volume (FINRA facilities)64.0% of 962,619 shares on November 20, 2026
5-day average short volume64.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$0.375 +0.62% today
52-week range · as of 2026-11-12 $0.303 – $1.63
Market cap
$77.14M
Volume
2.3M (0.2× avg)
3-mo avg 9.4M
Live data · 2026-11-21 05:21 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LUCD - Latest Insights

LUCD
Nov 12, 2026, 8:11 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.4212
Real-time Price: $0.375 info
Change: -$0.0462 (-11%) info
Market Cap: $77.141M info
LUCD
Nov 12, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4212
Real-time Price: $0.375 info
Change: -$0.0462 (-11%) info
Market Cap: $77.141M info
LUCD
Nov 12, 2026, 8:00 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $0.4212
Real-time Price: $0.375 info
Change: -$0.0462 (-11%) info
Market Cap: $77.141M info
LUCD
Oct 22, 2026, 6:18 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.5152
Real-time Price: $0.375 info
Change: -$0.1402 (-27%) info
Market Cap: $77.141M info
LUCD
Oct 22, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3584
Real-time Price: $0.375 info
Change: +$0.0166 (+5%) info
Market Cap: $77.141M info
LUCD
Oct 16, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.488401
Real-time Price: $0.375 info
Change: -$0.113401 (-23%) info
Market Cap: $77.141M info
LUCD
Sep 22, 2026, 9:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.860
Real-time Price: $0.375 info
Change: -$0.485 (-56%) info
Market Cap: $77.141M info
LUCD
Aug 13, 2026, 8:23 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.971
Real-time Price: $0.375 info
Change: -$0.596 (-61%) info
Market Cap: $77.141M info
LUCD
Aug 12, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.9877
Real-time Price: $0.375 info
Change: -$0.6127 (-62%) info
Market Cap: $77.141M info
LUCD
Jun 24, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.375 info
Change: -$0.650 (-63%) info
Market Cap: $77.141M info
LUCD
May 15, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $0.375 info
Change: -$0.665 (-64%) info
Market Cap: $77.141M info
LUCD
May 13, 2026, 4:41 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.375 info
Change: -$0.675 (-64%) info
Market Cap: $77.141M info
LUCD
May 13, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.375 info
Change: -$0.675 (-64%) info
Market Cap: $77.141M info
LUCD
Apr 30, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $1.09
Real-time Price: $0.375 info
Change: -$0.7151 (-66%) info
Market Cap: $77.141M info
LUCD
Apr 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.375 info
Change: -$0.695 (-65%) info
Market Cap: $77.141M info
LUCD
Apr 23, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.14
Real-time Price: $0.375 info
Change: -$0.7634 (-67%) info
Market Cap: $77.141M info
LUCD
Apr 20, 2026, 5:09 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $0.375 info
Change: -$0.9228 (-71%) info
Market Cap: $77.141M info
LUCD
Mar 26, 2026, 5:00 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.13
Real-time Price: $0.375 info
Change: -$0.755 (-67%) info
Market Cap: $77.141M info
LUCD
Mar 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $0.375 info
Change: -$0.895 (-70%) info
Market Cap: $77.141M info
LUCD
Mar 25, 2026, 6:19 PM EDT
Filing Type: S-3/A
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $0.375 info
Change: -$0.8376 (-69%) info
Market Cap: $77.141M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets